Related references
Note: Only part of the references are listed.Targeting immune suppressing myeloid-derived suppressor cells in oncology
Johnny Kao et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2011)
Myelosuppression by sunitinib is flt-3 genotype dependent
N. P. van Erp et al.
BRITISH JOURNAL OF CANCER (2010)
Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populations
Amanda L. Boehm et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Vaccination of Metastatic Renal Cancer Patients with MVA-5T4: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
Robert J. Amato et al.
CLINICAL CANCER RESEARCH (2010)
Sunitinib impairs the proliferation and function of human peripheral T cell and prevents T-cell-mediated immune response in mice
Yanhong Gua et al.
CLINICAL IMMUNOLOGY (2010)
Effect of a small molecule BCL-2 inhibitor on immune function and use with a recombinant vaccine
Benedetto Farsaci et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Mast Cells Mobilize Myeloid-Derived Suppressor Cells and Treg Cells in Tumor Microenvironment via IL-17 Pathway in Murine Hepatocarcinoma Model
Zhuoshun Yang et al.
PLOS ONE (2010)
The reverse side of the victory: Flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases
Ingrid M. E. Desar et al.
ACTA ONCOLOGICA (2009)
Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species
Joshua Oe Haznedar et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Vaccination strategies in patients with renal cell carcinoma
Anne Marie Asemissen et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies
Junko Ozao-Choy et al.
CANCER RESEARCH (2009)
Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients
Jennifer S. Ko et al.
CLINICAL CANCER RESEARCH (2009)
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
Suzanne Ostrand-Rosenberg et al.
JOURNAL OF IMMUNOLOGY (2009)
Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity
Kiavash Movahedi et al.
BLOOD (2008)
Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients
James H. Finke et al.
CLINICAL CANCER RESEARCH (2008)
Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma
Naeem Bhojani et al.
EUROPEAN UROLOGY (2008)
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane
Harold J. Burstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
KIT mutations in GIST
Jonathan A. Fletcher et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2007)
Sunitinib: From rational design to clinical efficacy
Laura Q. M. Chow et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
George D. Demetri et al.
LANCET (2006)
Share Paper
